Loading...
•
Sep 30, 2025
I-Mab Q3 2025 Earnings Report
Estimated EPS:-$0.05
Key Takeaways
NovaBridge Biosciences (formerly I-Mab) has transitioned to a 'Global Biotechnology Platform 3.0' model, focusing on bridging Asian innovation to global markets. The company maintains a strong cash position of $228.3 million with a runway extending into Q4 2028, while advancing a clinical-stage pipeline led by the CLDN18.2 x 4-1BB bispecific antibody, givastomig.
Givastomig demonstrated a 75% ORR and 16.9-month mPFS in Phase 1b combination trials for 1L gastric cancer.
The company successfully spun off its ophthalmology asset VIS-101 into a NewCo (Visara) with a 65% equity stake.
NovaBridge maintains a robust balance sheet with $228.3 million in cash and no outstanding debt.
Strategic focus has shifted to a 'Hub-and-Spoke' model to accelerate clinical de-risking and value creation for early-stage assets.
Forward Guidance
NovaBridge is entering a catalyst-rich period with multiple Phase 2 readouts and the initiation of global registrational studies expected through 2026 and 2027.
Positive Outlook
- Givastomig Phase 1b topline data expected in January 2026.
- VIS-101 Phase 2 topline data in wet AMD expected in Q1 2026.
- Initiation of a global randomized Phase 2 study for givastomig in 1L GEA.
- Planned expansion into 1L Pancreatic Cancer and Biliary Tract Cancer in 1H 2026.
- Cash runway secured for nearly three years of operations.
Challenges Ahead
- High clinical risk associated with early-phase (Phase 1b/2) oncology assets.
- Heavy reliance on third-party partners like ABL Bio and BMS for clinical execution.
- Potential for immune-related gastritis (observed in 33% of givastomig patients) to impact safety perceptions.
- Intense competition in the CLDN18.2 space from approved therapies like zolbetuximab.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...